Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2017 Earnings Results

Alnylam Pharmaceuticals Misses on EPS, Stock Down 4.73%

Alnylam Pharmaceuticals reported a wider-than-expected loss per share, which contributed to a decline in stock price by 4.73%. The lack of revenue data and absence of guidance updates left investors uncertain about the company's future performance. Management's cautious tone suggests they are facing challenges but remain focused on long-term strategies.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-1.20	N/A	+10.50%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed caution regarding current market conditions. They highlighted their commitment to long-term growth despite recent performance.

Management acknowledged the ongoing challenges in the market.

They emphasized a focus on long-term strategies despite short-term setbacks.

Alnylam Pharmaceuticals Misses on EPS, Stock Down 4.73%

Key numbers

Management commentary

Alnylam Pharmaceuticals, Inc.

More earnings this week

Alnylam Pharmaceuticals Misses on EPS, Stock Down 4.73%

Key numbers

Management commentary